189 related articles for article (PubMed ID: 26421925)
1. Dynamic FDG-PET Imaging to Differentiate Malignancies from Inflammation in Subcutaneous and In Situ Mouse Model for Non-Small Cell Lung Carcinoma (NSCLC).
Yang Z; Zan Y; Zheng X; Hai W; Chen K; Huang Q; Xu Y; Peng J
PLoS One; 2015; 10(9):e0139089. PubMed ID: 26421925
[TBL] [Abstract][Full Text] [Related]
2. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
[TBL] [Abstract][Full Text] [Related]
3. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
5. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
[TBL] [Abstract][Full Text] [Related]
6. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
8. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of FET and FDG for differentiating lung carcinoma from inflammation in mice.
Chang CH; Wang HE; Wu SY; Fan KH; Tsai TH; Lee TW; Chang SR; Liu RS; Chen CF; Chen CH; Fu YK
Anticancer Res; 2006; 26(2A):917-25. PubMed ID: 16619487
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
12. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
[TBL] [Abstract][Full Text] [Related]
15. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
Christensen JD; Colby TV; Patz EF
Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
19. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
[TBL] [Abstract][Full Text] [Related]
20. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
